Intranasal beclomethasone inhibits antigen-induced nasal hyperresponsiveness to histamine.
To determine whether intranasal steroid treatment inhibits the increased sensitivity to histamine that occurs 24 hours after nasal antigen challenge, 12 allergic volunteers were entered into a double-blind study comparing placebo or 164 micrograms of beclomethasone dipropionate twice a day for 7 days. Beclomethasone dipropionate partially reduced the early mediator response to antigen and the influx of eosinophils 24 hours later. Comparing the initial histamine challenge with that done 24 hours after antigen with the subjects on placebo, there was a significant increase in sneezes, TAME-esterase activity, and albumin. Pretreatment with intranasal beclomethasone dipropionate resulted in a reduced response to histamine 24 hours after antigen challenge. A positive correlation occurred between the number of eosinophils in the lavage before histamine challenge and the level of TAME-esterase activity (rs = 0.67, p = 0.03) during the histamine challenge that followed antigen with the subjects on placebo. We thus confirmed the increase in nonspecific nasal airway responsiveness 24 hours after antigen challenge, with a concomitant increase in eosinophils, and demonstrate its inhibition by pretreatment with intranasal steroids.
Baroody
F M
FM
Johns Hopkins University School of Medicine, Department of Medicine, Baltimore, MD.
Cruz
A A
AA
Lichtenstein
L M
LM
Kagey-Sobotka
A
A
Proud
D
D
Naclerio
R M
RM
D000281:Administration, Intranasal; D000941:Antigens / Q000276:immunology*; D001507:Beclomethasone / Q000008:administration & dosage / Q000494:pharmacology*; D004804:Eosinophils / Q000187:drug effects; D006632:Histamine / Q000494:pharmacology*; D006801:Humans; D009297:Nasal Mucosa / Q000187:drug effects* / Q000276:immunology; D010447:Peptide Hydrolases / Q000032:analysis
D000941:Antigens; D006632:Histamine; D010447:Peptide Hydrolases; C023073:tosylarginine methyl ester hydrolase; D001507:Beclomethasone